Elissa S. Cote
CIK: 0002069951
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
VTGN
Vistagen Therapeutics, Inc.
Officer
Discretionary Trading P&L
Holdings
About Cote Elissa S.
Cote Elissa S. (SEC CIK 0002069951) files insider reports with the SEC as Chief Corp Development Officer of Vistagen Therapeutics, Inc. (VTGN).
Signal8 holds 3 ownership filings by Cote Elissa S. (1 Form 3, 2 Form 4), filed between Jun 25, 2025 and Apr 9, 2026. Those filings report 2 transactions, from Jun 23, 2025 to Apr 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cote Elissa S.'s filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Cote Elissa S.
Other insiders filing for Vistagen Therapeutics, Inc. (VTGN)
- Williamson Douglas J, Officer
- Adler Reid G., Chief Legal Officer
- Tressler Nick B., Chief Financial Officer
- Singh Shawn, President and CEO
- Angelov Angel S, Chief Medical Officer
- Prince Joshua S., Chief Operating Officer